Methadone 40mg

Methadone 40mg


Methadone hydrochloride tablets for oral suspension contain methadone, an opioid agonist indicated for the:

  • Detoxification treatment of opioid addiction (heroin or other morphine-like drugs).
  • Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services.

Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec 8.

  • Description
  • Size Guide



Methadone hydrochloride tablets for oral suspension are contraindicated in patients with:

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity (e.g., anaphylaxis) to methadone or any other ingredient in methadone hydrochloride tablets for oral suspension



  • Serious, life-threatening, or fatal respiratory depression has been reported with the use of methadone, even when used as recommended. Patients with chronic pulmonary disease, elderly, cachectic, or debilitated patients may be at increased risk. Monitor closely, especially during initiation and titration.
  • Concomitant use of methadone and benzodiazepines or other CNS depressants increases the risk of respiratory depression, profound sedation, coma, and death.
  • Inform patients and caregivers that potentially fatal additive effects may occur if methadone hydrochloride tablets for oral suspension are used with benzodiazepines or other CNS depressants, including alcohol. Counsel patients that such medications should not be used concomitantly unless supervised by a healthcare provider. Educate patients about the risks of concomitant use of benzodiazepines, sedatives, opioid analgesics, or alcohol as a routine part of orientation to methadone treatment.
  • Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. These cases appear to be more commonly associated with, but not limited to, higher dose treatment (> 200 mg/day). Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Monitor patients with risk factors for development of prolonged QT interval, a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction.
  • Keep methadone hydrochloride tablets for oral suspension out of reach of children to prevent accidental ingestion.
  • Concomitant use of methadone hydrochloride tablets with CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors, may increase plasma concentrations of methadone and use with CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers or discontinuation of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors in patients treated with methadone hydrochloride tablets may decrease methadone plasma concentrations.
  • Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Observe newborns for signs of NOWS and manage accordingly; NOWS may be life threatening if not recognized and treated in neonates.
  • Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of methadone hydrochloride tablets for oral suspension with serotonergic drugs. Discontinue methadone hydrochloride tablets for oral suspension if serotonin syndrome is suspected.
  • Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. If adrenal insufficiency is diagnosed, treat with physiologic replacement of corticosteroids and wean patient off of the opioid until adrenal function recovers.
  • Methadone may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. Monitor during initiation and/or titration of methadone.
  • Use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Use of methadone should be avoided in patients with impaired consciousness or coma.
  • Methadone may increase frequency of seizures in patients with seizure disorders, and increase the risks of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control.
  • Avoid use of methadone hydrochloride with mixed agonist/antagonists or partial agonist analgesics due to risk of precipitation of withdrawal symptoms. When discontinuing methadone hydrochloride tablets for oral suspension, gradually taper the dosage.
  • Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of methadone hydrochloride tablets for oral suspension and know how they will react to the medication.
  • False positive urine drug screens for methadone have been reported for several drugs including diphenhydramine, doxylamine, clomipramine, chlorpromazine, thioridazine, quetiapine, and verapamil.



The most frequently observed adverse reactions included lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. This is not a complete list of potential adverse events associated with methadone. Please see Full Prescribing Information for a complete list.

Description methadone hydrochloride tablets for oral suspension, 40 mg
Generic Name methadone hydrochloride tablets for oral suspension, 40 mg
Rating AA
You've just added this product to the cart: